Meta-analysis to further assess the efficacy of mepolizumab 100mg SC on selected endpoints and to further investigate the relationship between efficacy endpoints, blood eosinophils and other important subgroups

Trial description: This is an umbrella study which will cover multiple objectives for pooled analysis of the mepolizumab studies MEA115588 (MENSA) and 200862 (MUSCA) in severe eosinophilic asthma. MEA115588 was a Phase III placebo controlled study which evaluated both 75 mg intravenous (IV) dose and a 100 mg SC dose of mepolizumab given for 32 weeks and 200862 was a Phase IIIb placebo controlled study which evaluated 100 mg SC dose of mepolizumab given for 24 weeks. This analysis will be performed to estimate the effect of mepolizumab 100 mg SC on exacerbation rates and other endpoints in subjects with severe eosinophilic asthma and to further investigate the relationship between efficacy endpoints and blood eosinophils and other important baseline characteristics. Subjects who were randomized to mepolizumab 100 mg SC or placebo across studies MEA115588 and 200862 will be included in the analysis. The effect of the 100 mg SC dose of mepolizumab will be compared to placebo and the estimated treatment differences at the end of study (Week 32 for MEA115588 and Week 24 for 200862) will be combined for each endpoint.